Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical Sector

Antimicrobial resistance is a pressing global health threat fueled by a complex interplay of biological, social, and economic factors. Despite widespread recognition of its impact, the antimicrobial resistance crisis continues to deepen because of inadequate innovation, poor access to effective treatments, and irrational antimicrobial use. Effectively combating antimicrobial resistance requires a multisectoral, multistakeholder, and multidimensional approach, with the pharmaceutical industry playing a pivotal role in new antimicrobial discovery along with diagnostic and other stakeholders. This review critically examines the central role of the pharmaceutical industry in addressing antimicrobial resistance, focusing on drug discovery, manufacturing practices, and stewardship efforts. While the industry has made notable contributions through the development of new antimicrobials and alternative approaches such as drug repurposing, artificial intelligence-driven discovery, and improved diagnostics, major challenges persist-including a declining antibiotic pipeline, limited access in low- and middle-income countries, antimicrobial pollution, irrational fixed-dose combinations, and the prevalence of substandard or falsified drugs. To overcome these barriers, this review explores strategic directions, including public-private partnerships, delinked incentive models, small-molecule innovation, ethical marketing, and equitable access strategies. It also underscores the industry's responsibility in promoting antimicrobial stewardship, participating in global surveillance systems, and educating prescribers and the public on responsible use. Future directions highlight the need for diversified funding, global collaboration, and the adoption of the "triple shield" approach-integrating infection prevention and control, antimicrobial stewardship, and robust surveillance to combat antimicrobial resistance. This review presents an integrated analysis of pharmaceutical accountability, highlighting actionable pathways that align innovation with equitable access, environmental safety, and ethical governance. By bridging gaps between discovery and delivery, the pharmaceutical sector can become a driving force in the global response to antimicrobial resistance.